Frequency Therapeutics, Inc. (FREQ)

NASDAQ: FREQ · IEX Real-Time Price · USD
5.14 -0.05 (-0.96%)
Jan 14, 2022 4:00 PM EST - Market closed

Company Description

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases.

Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue.

The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone.

Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited.

The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Frequency Therapeutics, Inc.
Frequency Therapeutics Logo
CountryUnited States
Founded2014
IPO DateOct 3, 2019
IndustryBiotechnology
SectorHealth Care
Employees83

Contact Details

Address:
75 Hayden Avenue
Lexington, MA 02421
United States
Phone781 315 4600
Websitefrequencytx.com

Stock Details

Ticker SymbolFREQ
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$14.00
CIK Code1703647

Key Executives

NamePosition
David L. LucchinoCo-Founder, President, Chief Executive Officer and Director
Peter P. PfreundschuhChief Financial Officer
Wendy S. ArnoldChief People Officer
Dr. Christopher R. LooseCo­-Founder and Chief Scientific Officer
William J. McLean Ph.D.Co-founder and Senior Vice President of Hearing Biology and Translational Research
Richard J. MitranoVice President of Finance and Operations
Dr. Jeff HrkachSenior Vice President of Technology Development
Dr. Dana C. HiltChief Medical Officer
Dr. Carl P. LeBelChief Development Officer
Dr. William W. Chin M.D.Senior Vice President of Translational Medicine

Latest SEC Filings

DateTypeTitle
Dec 21, 20214Statement of changes in beneficial ownership of securities
Dec 10, 20218-KCurrent report
Dec 10, 2021424B5Prospectus [Rule 424(b)(5)]
Dec 9, 20218-KCurrent report
Nov 15, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 15, 20218-KCurrent report
Nov 9, 20218-KCurrent report
Nov 4, 20214Statement of changes in beneficial ownership of securities
Oct 21, 20218-KCurrent report
Oct 7, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings